[Effects of ribavirin aerosol on viral exclusion of patients with hand-foot-mouth
disease]. [Article in Chinese]
Author(s): Pan S(1), Qian J, Gong X, Zhou Y(2).
Affiliation(s): Author information:
(1)Department of Infectious Diseases, Shanghai Children's Medical Center,
Shanghai Jiaotong University School of Medicine, Shanghai 200127, China.
(2)Email: zhouyf99@126.com.
Publication date & source: 2014, Zhonghua Yi Xue Za Zhi. , 94(20):1563-6
OBJECTIVE: To explore the roles of ribavirin aerosol in the prevention and
treatment of hand-foot-mouth disease (HFMD).
METHODS: For this prospective, multicenter, randomized, double-blind and
placebo-controlled trial, a total of 300 HFMD outpatients from 3 class 3A
hospitals from July 2011 to June 2013 were divided into treatment (ribavirin
aerosol) and control (placebo) groups (n = 150 each). The age range was 6 months
to 6 years. The proportion of male and female was 1.5: 1. Temperature, herpes of
mouth and skin rash were observed before and after treatments. Before treatment
and 6-7 days after, their specimens of throat swab were collected and the levels
of EV71 and CA16 detected with reverse transcription (RT)-PCR. The software SAS
9.2 was used for statistic data analyses.
RESULTS: Before treatment, no significant statistical difference existed in
parameters between treatment and control groups (all P > 0.05). After treatment,
the degree of herpes of mouth and papulovesicle of skin in treatment group was
better than that in control group (100.0% (147/147) vs 83.9% (120/143), χ(2) =
109.21, P < 0.01); (100.0% (147/147) vs 95.9% (139/145) , χ(2) = 6.38, P < 0.05)
. The virus negative conversion rates had significant inter-group difference
(80.0% (102/110) vs 41.8% (41/98) , χ(2) = 37.06, P < 0.01). The temperature,
compliance and differences were not significant (all P > 0.05). The effective
rate of comprehensive efficacy in treatment group was higher than that in control
group (93.9% (122/130) vs 52.0% (64/123), χ(2) = 111.08, P < 0.01). No obvious
adverse drug reaction was observed.
CONCLUSIONS: Ribavirin aerosol has multiple advantages of lower dose, quicker
onset, higher local concentration, better clinical efficacy and fewer
side-effects. Its therapeutic effect for local lesion is better than that for
systemic lesion. Thus it may shorten the duration of oropharyngeal and skin
lesions and lower the number and time of viral release.
|
